Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

By S. Antonia, J. López-Martín, J. Bendell, P. Ott, Matthew H. Taylor, J. Eder, D. Jäger, C. Pietanza, D. Le, F. Braud and 14 more. The Lancet Oncology, 2016

1,151 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/450e2b1cc645abcc2c045eb2affe35161c7e550f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “001) (Figure 2).(14-50) The predicted incidence of hypothyroidism ranged from 3.”
Combination of CTLA-4 and PD-1 blockers for treatment of cancer (2019, result): “…Phase 1/2 NCT01928394 ≥ 12 weeks ORR, 23% Median OS, 7.7 months 1-year OS rate, 43% Median PFS, 2.6 months 1-year PFS rate, 19% Grade 3-4 AEs, 30% Antonia et al 2016 Untreated advanced NSCLC Phase 1 NCT01454102 > 9 months ORR, 47% Median PFS, 8.1 months 24-week PFS rate, 68% Grade 3-4 AEs,…”
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities (2021, background): “Despite the addition of immunotherapy to platinumbased frontline chemotherapy, the absolute improvements in progression-free survival (PFS) and overall survival (OS) are modest (Antonia et al., 2016; Chung et al., 2020; Horn et al., 2018; Paz-Ares et al., 2019).”
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. (2018, neutral): “3 (1-57) 10 (43) 9 (69) Pulmonary 6 (5) 1 (1) 10.”
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018, neutral): “Increased lipase level 90 (16) 56 (10) 58 (11) 35 (7)”
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, methodology): “On 17 August, 2018, the FDA has also approved nivolumab for small-cell lung cancer (SCLC) patients who progressed on platinum therapy and at least one other line of therapy based on the CheckMate-032 trial, a phase 1/2 multi-center, multi-cohort study, which showed an increase in overall response ra”
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (2018, neutral): “Hemorrhagic/thrombotic 2 (4) 1 (3) 0 1 (5)”